IL149990A0 - Selective estrogen receptor modulators in combination with estrogens - Google Patents

Selective estrogen receptor modulators in combination with estrogens

Info

Publication number
IL149990A0
IL149990A0 IL14999001A IL14999001A IL149990A0 IL 149990 A0 IL149990 A0 IL 149990A0 IL 14999001 A IL14999001 A IL 14999001A IL 14999001 A IL14999001 A IL 14999001A IL 149990 A0 IL149990 A0 IL 149990A0
Authority
IL
Israel
Prior art keywords
estrogens
combination
estrogen receptor
receptor modulators
selective estrogen
Prior art date
Application number
IL14999001A
Other languages
English (en)
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of IL149990A0 publication Critical patent/IL149990A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14999001A 2000-01-28 2001-01-26 Selective estrogen receptor modulators in combination with estrogens IL149990A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17860100P 2000-01-28 2000-01-28
PCT/CA2001/000086 WO2001054699A1 (en) 2000-01-28 2001-01-26 Selective estrogen receptor modulators in combination with estrogens

Publications (1)

Publication Number Publication Date
IL149990A0 true IL149990A0 (en) 2002-12-01

Family

ID=22653187

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14999001A IL149990A0 (en) 2000-01-28 2001-01-26 Selective estrogen receptor modulators in combination with estrogens

Country Status (21)

Country Link
US (3) US20030040510A1 (cs)
EP (1) EP1251855A1 (cs)
JP (1) JP2003520817A (cs)
KR (1) KR20020073566A (cs)
CN (1) CN1400904A (cs)
AR (1) AR035564A1 (cs)
AU (1) AU2991301A (cs)
BR (1) BR0108107A (cs)
CA (1) CA2395730A1 (cs)
CZ (1) CZ20022401A3 (cs)
HK (1) HK1048761A1 (cs)
HU (1) HUP0204211A3 (cs)
IL (1) IL149990A0 (cs)
MX (1) MXPA02007165A (cs)
NO (1) NO20023484L (cs)
NZ (1) NZ534348A (cs)
PL (1) PL357163A1 (cs)
RU (1) RU2342145C2 (cs)
SK (1) SK9592002A3 (cs)
WO (1) WO2001054699A1 (cs)
ZA (1) ZA200205926B (cs)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11513390A (ja) * 1995-10-06 1999-11-16 アーチ デベロップメント コーポレイション 細胞殺傷のウイルス増強のための方法および組成物
US6358991B2 (en) * 2000-07-06 2002-03-19 American Home Products Corporation Methods of treating neuropeptide Y-related conditions
CA2414111A1 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
WO2003004033A1 (en) * 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
SK622004A3 (en) 2001-07-31 2004-08-03 Pfizer Prod Inc Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
TW200307553A (en) * 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
DK1509215T3 (da) * 2002-06-06 2007-03-12 Hormos Medical Ltd Behandling eller forebyggelse af urogenital atrofi og dets symptomer hos kvinder
PL1499278T3 (pl) * 2003-05-23 2005-09-30 Msd Oss Bv Farmaceutyczna postać użytkowa o natychmiastowym uwalnianiu zawierająca polimorficzny tibolon
WO2005073190A1 (en) * 2004-01-29 2005-08-11 Eli Lilly And Company Selective estrogen receptor modulators
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
EP2407462B1 (en) 2004-09-21 2014-07-30 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy
CN106138065A (zh) * 2004-10-20 2016-11-23 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
BRPI0608154A2 (pt) * 2005-02-16 2016-10-11 Wyeth Corp métodos de tratar ou inibir mucosite, cistite por radiação em um indivíduo, e de tratar pelo menos um sintoma de exposição de um indivíduo a um agente citotóxico ou à radiação, e, composição farmacêutica
AU2007256718A1 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
WO2008002490A2 (en) * 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
WO2008101030A1 (en) * 2007-02-13 2008-08-21 The Regents Of The University Of California Methods for amplifying steroid hormone effects
WO2008099060A2 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
KR101510646B1 (ko) 2007-02-14 2015-04-10 호르모스 메디칼 리미티드 치료적으로 유용한 트리페닐부텐 유도체의 제조 방법
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20140040862A1 (en) * 2008-04-03 2014-02-06 Adobe Systems Incorporated Copying Reusable Components from a Remote Source
AU2016235019B2 (en) * 2009-06-16 2018-06-28 Endorecherche, Inc. Treatment of alzheimer's disease, loss of cognition, memory loss, and dementia with sex steroid precursors in combination with selective estrogen receptor modulators
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
SI2568806T1 (sl) 2010-05-12 2016-09-30 Radius Health, Inc. Režimi zdravljenja
BR112012031464A2 (pt) 2010-06-10 2020-08-04 Aragon Pharmaceuticals, Inc. moduladores do receptor de estrogênio e os seus usos
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
EP2635121B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
EA201490897A1 (ru) 2011-12-16 2015-03-31 Олема Фармасьютикалс, Инк. Новые бензопирановые соединения, композиции и их применение
CN102584687A (zh) * 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
US9161940B2 (en) * 2012-02-14 2015-10-20 Repros Therapeutics Inc. Selective estrogen receptor modulators with short half-lives and uses thereof
CN102631677A (zh) * 2012-04-19 2012-08-15 中国农业大学 一种预防和/或治疗动脉粥样硬化的药物组合物
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2909164A1 (en) 2012-10-19 2015-08-26 Fermion Oy A process for the preparation of ospemifene
CA2889770A1 (en) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
EP4035664A3 (en) 2014-03-28 2022-11-30 Duke University Treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
HUE054998T2 (hu) 2015-02-02 2021-10-28 Mei Pharma Inc Kombinációs terápiák emlõrák kezelésében való alkalmazásra
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
PL3525774T3 (pl) 2016-10-11 2022-04-25 Duke University Leczenie lazofoksyfenem raka piersi er+
DK3565542T3 (da) 2017-01-05 2024-07-01 Radius Pharmaceuticals Inc Polymorphic forms of rad1901-2hcl
US20180207177A1 (en) * 2017-01-23 2018-07-26 Government Of The United States As Represented By The Secretary Of The Air Force TREATMENT OF TRIPLE NEGATIVE BREAST CANCER UTILIZING ANDROST-5-ENE-3b,17b-DIOL (b-AED), ANDROST-5-ENE-3b,7b,17b-TRIOL (b-AET) AND ESTRADIOL (E2)
WO2019199891A1 (en) 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
CN116508778B (zh) * 2023-03-02 2024-12-27 广西师范大学 一种新性信息素美雌醇的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5446061A (en) * 1993-11-05 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5446071A (en) * 1994-11-18 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
US5897539A (en) * 1995-09-28 1999-04-27 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
ATE206701T1 (de) * 1996-04-19 2001-10-15 American Home Prod Östrogene verbindungen
AR017256A1 (es) * 1997-08-21 2001-09-05 American Home Prod Compuestos de indol sustituidos, metodo para la sintesis en fase solida de los mismos, conjuntos de combinacion para ser empleados en dicho metodo, uso delos compuestos para preparar un medicamento y composiciones farmaceuticas que los comprenden
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
DE19916419B4 (de) * 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
AU5957500A (en) * 1999-07-06 2001-01-22 Endorecherche Inc. Methods of treating and/or suppressing weight gain

Also Published As

Publication number Publication date
BR0108107A (pt) 2003-03-11
EP1251855A1 (en) 2002-10-30
CZ20022401A3 (cs) 2003-10-15
US20020198179A1 (en) 2002-12-26
US20030040510A1 (en) 2003-02-27
SK9592002A3 (en) 2003-12-02
JP2003520817A (ja) 2003-07-08
AU2991301A (en) 2001-08-07
NZ534348A (en) 2006-06-30
KR20020073566A (ko) 2002-09-27
AR035564A1 (es) 2004-06-16
HUP0204211A3 (en) 2005-06-28
NO20023484D0 (no) 2002-07-22
HUP0204211A2 (hu) 2003-04-28
RU2342145C2 (ru) 2008-12-27
RU2002123047A (ru) 2004-03-10
MXPA02007165A (es) 2003-09-22
CN1400904A (zh) 2003-03-05
US20030065008A1 (en) 2003-04-03
CA2395730A1 (en) 2001-08-02
PL357163A1 (en) 2004-07-26
ZA200205926B (en) 2003-07-24
NO20023484L (no) 2002-07-22
HK1048761A1 (zh) 2003-04-17
WO2001054699A1 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
IL149990A0 (en) Selective estrogen receptor modulators in combination with estrogens
IL185087A0 (en) Selective estrogen receptor modulator in combination with a sex steroid precursor
HUP0204029A3 (en) Triphenylalkene derivatives and their use as selective estrogen receptor modulators
PL374215A1 (en) Selective estrogen receptor modulators
EG25606A (en) Glucocorticoid receptor modulators
EP1321847A4 (en) TEXT COMMUNICATION DEVICE
EP1170354A4 (en) DRY DISTILLATION / VOLUME REDUCTION DEVICE FOR WASTE
AU2001258341A1 (en) 8beta-hydrocarbyl-substituted estratrienes for use as selective estrogens
SI1076558T1 (en) 2-phenyl-1-(-(2-aminoethoxy)-benzyl -indole in combination with estrogens
GB0001913D0 (en) Printing device
IL154984A0 (en) Estrogen receptor modulators
EP1226154A4 (en) ÖSTRADIOL CONJUGATES AND ITS USE
GB9913581D0 (en) Improvements in pollution control
SI1272504T1 (sl) 8beta-hidrokarbilno substituirani estratrieni kotestrogeni s selektivnim učinkom
GB9913649D0 (en) Estrogen receptor
GB0030037D0 (en) Novel estrogen receptor ligands and methods III
GB2355943B (en) Improvements in pollution control
GB9923289D0 (en) Mixing device
GB9927977D0 (en) Advance warning device for instruction in toilet use
HK1032007A (en) Selective estrogen receptor modulator in combination with denydroepiandrosterone (dhea) or analogues
GB0024319D0 (en) Mixing device
TW487193U (en) Pivot device
TW472538U (en) Seat for wind-powered flashing device
GB0016230D0 (en) Estrogen receptors
GB0010244D0 (en) Mixing device